All four (100%) non-endometrioid adenocarcinomas expressed HER2/neu receptor which was similar to the literature, and HER2/neu receptor was positive in 10% (two out of 20) of grade II and 100% in grade III tumors, four out of five (80%) of stage III and all stage IV tumors were HER2/neu receptor-positive [11]. This evidence concerns the gene ERBB2 and endometrioid adenocarcinoma.